Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )
|
NovAccess Global Inc. |
|
(Name of Issuer) |
|
Common Stock, no par value per share |
|
(Title of Class of Securities) |
|
98385L 10 2 |
|
(CUSIP Number) |
|
Christopher J. Hubbert 1375 East Ninth Street, 29th Floor Cleveland, Ohio 44114 216-736-7215 |
|
(Name, Address and Telephone Number of Person Authorized |
|
November 23, 2020 |
|
(Date of Event which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| SCHEDULE 13D |
| CUSIP No. 98385L 10 2 | Page 2 of 4 |
|
1 |
NAME OF REPORTING PERSONS Dwain K. Morris-Irvin |
|
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |
|
|
3 |
SEC USE ONLY |
|
|
4 |
SOURCE OF FUNDS OO |
|
|
5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
|
|
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
NUMBER OF |
7 |
SOLE VOTING POWER 1,800,000 |
|
8 |
SHARED VOTING POWER 0 |
|
|
9 |
SOLE DISPOSITIVE POWER 1,800,000 |
|
|
10 |
SHARED DISPOSITIVE POWER 0 |
|
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,800,000 |
|
|
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |
|
|
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14% |
|
|
14 |
TYPE OF REPORTING PERSON IN |
|
| SCHEDULE 13D |
| CUSIP No. 98385L 10 2 | Page 3 of 4 |
Item 1. Security and Issuer.
This Schedule 13D relates to shares of the common stock, without par value (the “common stock”), of NovAccess Global Inc. (the “Company”), a Colorado corporation with offices at 8834 Mayfield Road, Suite C, Chesterland, Ohio 44026, beneficially owned by Dr. Dwain K. Morris-Irvin, the Company’s chief executive officer.
Item 2. Identity and Background.
(a) This Schedule 13D is filed by Dr. Dwain K. Morris-Irvin.
(b) The business address of Dr. Irvin is 8834 Mayfield Road, Suite C, Chesterland, Ohio 44026.
(c) Dr. Irvin is the chief executive officer of the Company.
(d) During the last five years, Dr. Irvin has not been convicted in any criminal proceeding (excluding traffic violations).
(e) During the last five years, Dr. Irvin has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f) Dr. Irvin is a citizen of the United States of America.
Item 3. Source and Amount of Funds or Other Consideration.
Effective November 23, 2020, the Company issued 1.8 million unregistered shares (the “Shares”) of common stock to Dr. Irvin to compensate him for serving as the Company’s chief executive officer.
Item 4. Purpose of Transaction.
Dr. Irvin acquired the Shares as compensation for serving as the Company’s chief executive officer. As the chief executive officer of the Company, Dr. Irvin is involved in making strategic decisions relating to the Company. Other than as an officer of the Company, Dr. Irvin does not have any plans or proposals which relate to or would result in any of the events enumerated in Item 4 of Regulation 13d-101 under the Securities and Exchange Act of 1934 (“Regulation 13d-101”).
Item 5. Interest in Securities of the Issuer.
(a) Dr. Irvin is the record and beneficial owner of 1.8 million shares of common stock, which is 14% of the Company’s outstanding common stock on March 31, 2021.
(b) Dr. Irvin has the sole power to vote and to dispose of the Shares.
(c) Dr. Irvin has not engaged in any transactions in the common stock since acquiring the Shares.
(d) Dr. Irvin has the sole right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares.
| SCHEDULE 13D |
| CUSIP No. 98385L 10 2 | Page 4 of 4 |
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Dr. Irvin is not a party to any contract, arrangement, understanding or relationship with respect to any securities of the Company required to be disclosed pursuant to Item 6 of Regulation 13d-101.
Item 7. Material to be Filed as Exhibits.
Dr. Irvin is not a party to any agreement required to be filed pursuant to Item 7 of Regulation 13d-101.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated April 16, 2021 /s/ Dwain K. Morris-Irvin
Dwain K. Morris-Irvin